A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 88
- Registration Number
- NCT01358734
- Locations
- 🇺🇸
(240) Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸(160) The Western Pennsylvania Hospital- Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸(200) Coastal Integrative Cancer Care, San Luis Obispo, California, United States
A Rollover Study for Patients Who Participated in Other Romidepsin Protocols
- First Posted Date
- 2011-05-16
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 19
- Registration Number
- NCT01353664
- Locations
- 🇬🇧
Sarah Cannon Research UK, London, United Kingdom
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
- First Posted Date
- 2011-05-13
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Celgene
- Target Recruit Count
- 118
- Registration Number
- NCT01353625
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇩🇪Universitatsklinikum Wurzburg, Würzburg, Germany
🇺🇸UCLA, Los Angeles, California, United States
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 113
- Registration Number
- NCT01351935
- Locations
- 🇺🇸
University of Arizona SPORE, Tucson, Arizona, United States
🇺🇸Clearview Cancer Institute Oncology Specialties, P.C, Huntsville, Alabama, United States
🇺🇸University of California San Diego, La Jolla, California, United States
MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry
- Conditions
- First Posted Date
- 2011-05-05
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 149
- Registration Number
- NCT01347944
- Locations
- 🇮🇹
Dipartimento Onco - Ematologico Azienda Ospedaliera SS Antonio, Biagio e Cesare Arrigo, Alessandria, Italy
🇮🇹Ematologia Azienda Ospedaliera Universitaria Policlinico di Bari, Bari, Italy
🇮🇹Ematologia A.O. Ospedale Riuniti di Bergamo, Bergamo, Italy
Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 15
- Registration Number
- NCT01324310
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇬🇧Sarah Cannon Research UK, London, United Kingdom
Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 14
- Registration Number
- NCT01324323
- Locations
- 🇬🇧
Sarah Cannon Research UK, London, United Kingdom
🇺🇸Sarah Canon Research Institute, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 74
- Registration Number
- NCT01324947
- Locations
- 🇪🇸
Hospital de Donostia - Hematology, Guipúzcoa, Spain
🇨🇦Royal Victoria Hospital, Montreal, Quebec, Canada
🇦🇺Border Medical Oncology, Wodonga, Australia
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
- First Posted Date
- 2011-03-28
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 120
- Registration Number
- NCT01323751
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
- First Posted Date
- 2011-03-09
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 455
- Registration Number
- NCT01311687
- Locations
- 🇧🇪
CHU UCL Mont-Godinne-Dinant asbl, Yvoir, Belgium
🇷🇺St. Petersburg Research Institute of Hematology and Blood Transfusion, St. Petersburg, Russian Federation
🇷🇺State Institution Moscow Regional Research Clinical Institute, Moscow, Russian Federation